## **PATENT**

- 10. (new) The method of claim 8 wherein the human  $\alpha$ -interferon is obtained from a lymphoblastoid cell culture.
- In the method of claim 7 wherein the human  $\alpha$ -interferon is obtained from a lymphocyte cells.
- 12. (new) The method of claim 8 wherein the human  $\alpha$ -interferon is obtained from a lymphocyte cells.
- 13. (new) The method of claim 7 wherein the formulation is administered in a single dosage unit having a volume of approximately 1 milliliter.
- 14. (new) The method of claim 8 wherein the formulation is administered in a single dosage unit having a volume of approximately 1 milliliter.
- 15. (new) The method of claim 9 wherein the formulation is administered in a single dosage unit having a volume of approximately 1 milliliter.
- 16. (new) The method of claim 10 wherein the formulation is administered in a single dosage unit having a volume of approximately 1 milliliter.

## **PATENT**

17. (new) The method of claim 11 wherein the formulation is administered in a single dosage unit having a volume of approximately 1 milliliter.

18. (new) The method of claim 12 wherein the formulation is administered in a single dosage unit having a volume of approximately 1 milliliter.

19. (new) A liquid pharmaceutical composition for oral administration comprising natural human  $\alpha$ -interferon at a concentration between 100 IU/ml and 500 IU/ml, wherein the  $\alpha$ -interferon is obtained from cells of the group consisting of lymphoblastoid cell cultured cells and lymphocyte cells.

Dated: September 15, 2000

Respectfully submitted,

Ronald B. Hildreth

Patent Office Reg. No. 19,498

Lisa B. Kole

Patent Office Reg. No. 35,225

Attorneys for Applicants (212) 408-2500

Enclosures